Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods (Q34459840)

2 August 2017

1 reference

title

Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods (English)

1 reference

2 August 2017

0 references

1 reference

2

G Chêne

1 reference

2 August 2017

V Journot

1

1 reference

2 August 2017

P Joly

3

1 reference

2 August 2017

M Savès

4

1 reference

2 August 2017

H Jacqmin-Gadda

5

1 reference

2 August 2017

J M Molina

6

1 reference

2 August 2017

R Salamon

7

1 reference

2 August 2017

ALBI Study Group

8

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Contemporary Clinical Trials

2 August 2017

1 reference

2 August 2017

22

1 reference

2 August 2017

6

1 reference

2 August 2017

639-658

1 reference

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Use of virologic markers in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Analysis of HIV-1 clinical trials: statistical magic?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Longitudinal models for AIDS marker data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious D

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

An approach to the analysis of repeated measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Unequally spaced longitudinal data with AR(1) serial correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Mixed effects models with censored data with application to HIV RNA levels

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Analysis of left-censored longitudinal data with application to viral load in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

Virologic and regimen termination surrogate end points in AIDS clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

A new approach to the analysis of clinical drug trials with withdrawals.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900158-1

7 January 2021

10.1016/S0197-2456(01)00158-1

Identifiers

DOI

1 reference

2 August 2017

1 reference